Ibio Inc (IBIO) Stock Price, Quote & News

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology

Sector: Healthcare

Phone: 979 446 0027

Website: ibioinc.com

Address:

11750 Sorrento Valley Road, Suite 200, San Diego, United States

Retail_Lives_Matter Jan. 20 at 5:00 PM

$IBIO go away Karen @BuyBigly 😂😂😂

1 · Reply

Shorting_BTC_Since_2009 Jan. 20 at 3:34 AM

$IBRX I loved the interview. Trump will step in within a month IMO. Also revenue will explode this year no matter what happens! $META $IBIO $NVDA $BTC.X

0 · Reply

BuyBigly Jan. 20 at 3:07 AM

$IBIO 🙄 posting old articles to pump this garbage. We all remember it very well, much more than you will ever know.

1 · Reply

1Powar Jan. 20 at 2:54 AM

$IBIO what an interesting article. How well to you know iBios past? https://www.dvidshub.net/news/514695/darpa-effort-speeds-biothreat-response

1 · Reply

1Powar Jan. 20 at 2:21 AM

$IBIO boom shakalaka boom

1 · Reply

1Powar Jan. 20 at 2:18 AM

$IBIO iBio own website. 8th paragraph down https://ir.ibioinc.com/news-events/press-releases/detail/65/ibio-forms-joint-venture-cmo-for-large-scale

0 · Reply

Retail_Lives_Matter Jan. 20 at 1:54 AM

$IBIO

1 · Reply

1Powar Jan. 20 at 12:27 AM

$IBIO

1 · Reply

1Powar Jan. 20 at 12:06 AM

$IBIO ladies an gentleman meet Dr Martin Brenner from Stranger Things with L and the rainbow. He unlock human potential to fight the underworld, did he not? Same name same concept. When will you wake up to the movie you are watching?

4 · Reply

Shorting_BTC_Since_2009 Jan. 19 at 6:32 PM

$IBRX $IBIO $IREN $MU this

0 · Reply

iBio Announces $26 Million Private Placement

Nov 24, 2025, 4:15 PM EST - 2 months ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 4:01 PM EST - 2 months ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Oct 30, 2025, 7:00 AM EDT - 2 months ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 23, 2025, 7:00 AM EDT - 3 months ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 21, 2025, 7:00 AM EDT - 3 months ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Sep 5, 2025, 7:30 AM EDT - 4 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Aug 25, 2025, 7:00 AM EDT - 5 months ago

iBio Announces Closing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 5 months ago

iBio Announces Pricing of $50 Million Public Offering

Aug 18, 2025, 4:01 PM EDT - 5 months ago

iBio Announces Proposed Public Offering

Jun 24, 2025, 7:00 AM EDT - 7 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 23, 2025, 4:15 PM EDT - 7 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 16, 2025, 7:00 AM EDT - 7 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

May 5, 2025, 8:00 AM EDT - 9 months ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 2, 2025, 8:00 AM EDT - 9 months ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

Apr 29, 2025, 1:43 PM EDT - 9 months ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 22, 2025, 8:00 AM EDT - 9 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 7, 2025, 7:00 AM EDT - 10 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Feb 19, 2025, 4:05 PM EST - 11 months ago

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 10, 2025, 4:05 PM EST - 1 year ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

Jan 2, 2025, 7:00 AM EST - 1 year ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 3, 2024, 7:00 AM EDT - 1 year ago

iBio to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Jun 3, 2024, 7:00 AM EDT - 1 year ago

iBio Closes Sale of Manufacturing Facility in Texas

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Mar 27, 2024, 2:43 PM EDT - 1 year ago

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 7:00 AM EDT - 1 year ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 26, 2024, 7:35 PM EDT - 1 year ago

iBio Announces $15.0 Million Private Placement

Feb 26, 2024, 7:45 AM EST - 2 years ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 6:50 AM EST - 2 years ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Jun 27, 2023, 8:00 AM EDT - 2 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

May 9, 2023, 4:30 PM EDT - 2 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

Apr 4, 2023, 4:05 PM EDT - 3 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Mar 31, 2023, 8:10 AM EDT - 3 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Feb 16, 2023, 4:48 PM EST - 3 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Dec 9, 2022, 4:05 PM EST - 3 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 3 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 4:01 PM EST - 3 years ago

iBio Announces Proposed Underwritten Public Offering

Retail_Lives_Matter Jan. 20 at 5:00 PM

$IBIO go away Karen @BuyBigly 😂😂😂

1 · Reply

Shorting_BTC_Since_2009 Jan. 20 at 3:34 AM

$IBRX I loved the interview. Trump will step in within a month IMO. Also revenue will explode this year no matter what happens! $META $IBIO $NVDA $BTC.X

0 · Reply

BuyBigly Jan. 20 at 3:07 AM

$IBIO 🙄 posting old articles to pump this garbage. We all remember it very well, much more than you will ever know.

1 · Reply

1Powar Jan. 20 at 2:54 AM

$IBIO what an interesting article. How well to you know iBios past? https://www.dvidshub.net/news/514695/darpa-effort-speeds-biothreat-response

1 · Reply

1Powar Jan. 20 at 2:21 AM

$IBIO boom shakalaka boom

1 · Reply

1Powar Jan. 20 at 2:18 AM

$IBIO iBio own website. 8th paragraph down https://ir.ibioinc.com/news-events/press-releases/detail/65/ibio-forms-joint-venture-cmo-for-large-scale

0 · Reply

Retail_Lives_Matter Jan. 20 at 1:54 AM

$IBIO

1 · Reply

1Powar Jan. 20 at 12:27 AM

$IBIO

1 · Reply

1Powar Jan. 20 at 12:06 AM

4 · Reply

Shorting_BTC_Since_2009 Jan. 19 at 6:32 PM

$IBRX $IBIO $IREN $MU this

0 · Reply

TreeShade Jan. 19 at 4:36 AM

$IBIO Brenner seems *very* happy to be leading a "failing" company. 🐂 Me thinks he knows whats happening ... 💸 💰 🤑

1 · Reply

Retail_Lives_Matter Jan. 18 at 5:07 PM

$IBIO @1Powar

0 · Reply

1Powar Jan. 18 at 4:26 PM

$IBIO for those who don’t clink links.

1 · Reply

1Powar Jan. 18 at 4:24 PM

$IBIO @Retail_Lives_Matter @TheSultann ok what’s up here https://www.forbes.com/sites/joelshulman/2026/01/16/the-fastest-path-to-greenland-runs-through-novo-nordisk/

1 · Reply

Retail_Lives_Matter Jan. 18 at 3:55 PM

$IBIO @1Powar https://investor.lilly.com/news-releases/news-release-details/nvidia-and-lilly-announce-co-innovation-ai-lab-reinvent-drug

0 · Reply

1Powar Jan. 18 at 8:02 AM

$IBIO This true?

0 · Reply

1Powar Jan. 18 at 2:33 AM

$IBIO Trump: A friend of mine—very smart, very rich, very powerful—but very fat. He took the fat drug. I won’t say which one. It was Ozempic. The drug doesn’t work on him. I saw him recently—he’s actually fatter than ever. https://x.com/clashreport/status/2012434806265589962?s=46

0 · Reply

smartmoney43 Jan. 17 at 10:51 PM

$IBIO solid 3-month chart 💪

0 · Reply

1Powar Jan. 17 at 9:17 PM

$IBIO ohhhh crap

1 · Reply

TheSultann Jan. 16 at 9:05 PM

$IBIO Another Novo Nordisk sneaking around liking our shit 👀 #2 JPM is all about Partnering

2 · Reply

TheSultann Jan. 16 at 5:57 PM

$IBIO 👀 Found her Lurking around IBIO’s Post from JPM 26 Ja Young Kim Muller - Novo Nordisk Old buddy or New Buddy of Benner’s 🧐 Did she like what she saw 🤔 What is An External Innovation Lead: External innovation leadership is about guiding a company to look outside its own walls—to startups, universities, customers, and partners—for new ideas, technologies, and talent, combining these external insights with internal R&D to create new products, disrupt markets, and accelerate growth, rather than just focusing on incremental improvements.

1 · Reply

TortillaDePatata Jan. 16 at 5:31 PM

$IBIO This is the important chart. $12 is the top.

0 · Reply

Market Cap	49.47M
Revenue (ttm)	400,000.00
Net Income (ttm)	-18.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,595.00%
Debt to Equity Ratio	0.01

Volume	1,359,000
Avg Vol	6,853,018
Day's Range	N/A - N/A
Shares Out	22.49M
Stochastic %K	24%
Beta	1.14
Analysts	Strong Sell
Price Target	$4.52